Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
YD Bio Moves Forward on Safe Save Medical Acquisition Through Binding LOI
YD Bio Limited announced a significant strategic milestone in expanding its immunocell therapy portfolio. The company has entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences Technology Co., Ltd., positioning itself to strengthen its competitive standing in advanced cellular therapeutics.
Strategic LOI Framework and Transaction Structure
The binding LOI represents a formal commitment by YD Bio to proceed with acquiring Safe Save Medical's specialized cell-based medical technologies and immunocell therapy platforms. As part of the transaction framework, the deal remains subject to customary closing conditions and regulatory approvals. YD Bio plans to consolidate Safe Save Medical's advanced capabilities and technological expertise into its existing operations, creating a more robust pipeline in the immunotherapy sector.
Consolidating Immunocell Therapy Capabilities
Safe Save Medical Cell Sciences Technology specializes in developing next-generation immunocell therapies and cell-based treatment solutions. By integrating these capabilities, YD Bio aims to accelerate its research and development efforts while broadening its therapeutic portfolio. The acquisition strategy underscores the company's long-term commitment to delivering cutting-edge biotechnology solutions and maintaining leadership in the rapidly evolving immunocell therapy landscape.
Market Position and Financial Snapshot
The transaction is anticipated to close following successful completion of due diligence processes and satisfaction of all customary conditions. YD Bio's current market standing reflects growing investor interest in the sector—YDES shares have traded within a range of $5.30 to $25.00, with recent trading activity showing the stock at $11.73, representing a 4.11% decline. This acquisition positions the company for sustained growth in an increasingly competitive immunotherapy market.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.